PRINCETON, N.J. , May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
PRINCETON, N.J. , April 28, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader
Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient...
Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is...
Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed its positioning in a landscape where modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism...
ORLANDO, FL / ACCESS Newswire / April 10, 2026 / RedChip Companies will air interviews with BIO-key International, Inc. (Nasdaq:BKYI), 20/20 Biolabs, Inc. (Nasdaq:AIDX), Society Pass Inc. (Nasdaq:SOPA),...
Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment of cutaneous T-cell lymphoma in Oncology...
HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor ® during 12-week treatment course
Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing its Phase 3 FLASH2 trial of HyBryte(TM) for cutaneous T-cell lymphoma with interim...